1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Vista Pharmaceuticals Limited

Vista Pharmaceuticals Limited

VISTAPH.BO
Vista Pharmaceuticals LimitedIN flagBombay Stock Exchange
7.11
INR
-0.22
- -
437.63MMarket Cap
Vista Pharmaceuticals Limited
VISTAPH.BO
(Bombay Stock Exchange)

Recent

price

7.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
3.78
2.41
4.98
5.53
5.5
6.15
8.88
9.76
10.3
7.5
0.34
0.11
0.27
2.36
1.71
- -
0.9
Revenue per Share
-0.19
-1.11
0.05
0.31
0.54
0.31
0.46
0.76
0.31
-1.21
-0.54
-0.24
-1.54
-1.03
-0.79
- -
-2
Basic EPS, GAAP
0.03
0.09
0.06
-0.06
-1.45
-1.1
-0.39
-5.27
-0.78
-0.3
-1.89
-0.27
-0.81
-1.31
-1.26
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3.78
2.67
2.72
3.03
2.36
2.81
3.16
3.91
4.14
2.9
1.15
1.87
0.38
-0.27
-0.5
- -
2.04
Book Value per Share
6.87
5.76
5.75
6.06
4.17
3.49
4.74
9.03
9.19
6.62
6.26
7
7.37
7.08
6.1
- -
4.46
Tangible Book Value per Share
15
15
15
15
25
25
27
29
30
30
37
37
37
44
59
- -
60
Basic Weighted Avg Shares
57
36
75
83
137
154
242
282
311
228
13
4
10
103
101
54
54
Sales/Revenue/Turnover
-5.08
-42.41
2.27
5.38
12.08
11.26
12.26
22.77
1.59
-26.99
-194.04
-462.9
-386.81
-37.93
-47.31
-284.57
-284.57
Operating Margin (%)
5
6
6
1
10
10
10
13
14
13
7
6
6
7
7
7
7
Depreciation Expense
-3
-17
1
5
14
8
12
22
9
-37
-20
-9
-57
-45
-46
-121
-121
Net Income, GAAP
- -
- -
52.74
1.36
- -
7.66
- -
22.66
18.12
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-5.15
-45.91
1.08
5.62
9.91
5.03
5.16
7.75
3.02
-16.16
-158.61
-225.19
-564.11
-43.86
-46.14
-223.38
-223.38
Profit Margin (%)
-32
-43
-36
-24
-2
-18
66
126
125
53
60
109
97
-12
24
-13
-13
Working Capital
- -
- -
- -
- -
- -
- -
60
59
60
55
87
74
52
29
24
18
18
LT Debt
103
86
86
91
104
116
166
319
358
296
328
355
367
405
454
364
364
Total Equity
- -
- -
0.93
4.97
- -
9.32
- -
13.82
0.89
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
1.99
10.82
- -
11.84
- -
15.63
9.64
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-10.32
-34.41
1.99
10.82
26.09
11.98
15.96
21.98
7.9
-34.55
-30.67
-15.86
-136.2
-83.28
- -
- -
-54.4
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
62
- -
81
LT Borrowings
23
- -
18
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
- -
62
Market Capitalization
601
485
369

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
158
- -
154
Cash, Cash Equivalents & STI
1
- -
1
Accounts Receivable, Net
41
- -
3
Inventories
76
- -
110
Total Current Liabilities
139
- -
166
Payables & Accruals
- -
- -
- -
ST Debt
62
- -
81
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.54%
2.84%
-19.77%
Free Cash Flow
198.24%
40.32%
-30.19%
Net Income, GAAP
16.61%
124.72%
159.45%
Sales/Revenue/Turnover
92.49%
192.41%
-46.4%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20
35
17
31
103
2025
18
25
26
32
101
2026
15
15
24
- -
54

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.23
-0.46
-0.33
- -
-1.03
2025
-0.15
-0.16
-0.21
-0.24
-0.79
2026
-0.22
-0.42
-0.41
-0.91
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Natural Capsules Limited (NATCAPSUQ.BO)
Parnax Lab Limited (PARNAXLAB.BO)
Paion AG (0NF3.L)
Orexigen Therapeutics, Inc. (OREX)
Sastasundar Ventures Limited (SASTASUNDR.NS)
Trident Lifeline Limited (TLL.BO)
Business
Vista Pharmaceuticals Limited (VISTAPH.BO) manufactures and markets over-the-counter and prescription generic drug products consisting of tablets, capsules, and liquids across various therapeutic categories including anti-inflammatory, analgesic, anti-pyretic, antibiotics, gynecological range, iron supplements, pain management, gastrointestinal, and veterinary preparations; the company also provides third-party manufacturing services and sells formulations to related entities engaged in pharmaceutical production. Founded in 1992 and headquartered in Hyderabad, India, with a USFDA-approved manufacturing facility in India and a marketing and distribution center in the USA, Vista Pharmaceuticals initially focused on the United States market, becoming the first Indian company to secure USFDA approvals for OTC and prescription drugs in 1994 and commence exports in 1996, while its Indian facility received USFDA approval for ANDA products in June 2010. The company operates primarily in the pharmaceuticals and biotechnology sector, targeting domestic Indian markets and international exports particularly to the US, with recent activities including a board meeting scheduled for November 13, 2025, to consider financial results and an annual general meeting on September 30, 2025, where eight resolutions passed including audited financials adoption, reappointments of managing and whole-time directors, and auditors.